Abstract: Provided are aromatic oligoamide foldamers and self-assembled compositions of the same. The aromatic oligoamide foldamers and compositions can form tube-like structures that can form pores in membranes. The pores can be used to transport ions and molecules, such as, for example, cryoprotective agents or therapeutic agents, through the membrane. The tube-like structures exhibit desirable stability at low temperatures.

Abstract: The present invention provides a compound having the structure: for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.

Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

Abstract: A dynamic phantom for use with a functional magnetic resonance imaging (fMRI) device is described. In one example, the dynamic phantom includes an outer housing, an inner cylinder including a removable divider, and a gearbox that can rotate the cylinder, all of which are made from fMRI-compatible materials. The divider forms longitudinal compartments inside the cylinder that can each contain a contrast material. When the cylinder contains contrast materials having at least two different concentrations, and a space between the cylinder and the housing also contains a contrast material, rotation of the cylinder produces biomimetic hemodynamic signals that may be detected by the fMRI device.

Abstract: The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IX? reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.

Abstract: A method of fabricating nanocomposite anode material embodying a lithium titanate (LTO)-multi-walled carbon nanotube (MWNT) composite intended for use in a lithium-ion battery includes providing multi-walled carbon nanotube (MWNTs), including nanotube surfaces, onto which functional oxygenated carboxylic acid moieties are arranged, generating 3D flower-like, lithium titanate (LTO) microspheres, including thin nanosheets and anchoring the acid-functionalized MWNTs onto surfaces of the 3D LTO microspheres by ?-? interaction strategy to realize the nanocomposite anode material.

Abstract: Provided are compositions and methods for enhancing recombinant protein production. The compositions and methods involve use of Ribose Binding Protein (RBP) as a segment of a fusion polypeptide, whereby the RBP segment enhances production of the fusion protein. The fusion proteins contain the RBP sequentially in a single fusion protein with a polypeptide for which enhanced expression is desired. Recombinant expression vectors encoding the fusion proteins that contain and RBP segment are included, as are cells that contain the expression vectors. Methods for separating fusion proteins and for liberating a polypeptide segment that is part of the fusion protein are also provided.

Abstract: A cart for dispensing, storing, and tracking medical instruments is provided. The cart has a housing, a first motor, a second motor, one or more trays, and a processor. The trays hold one or more medical instruments, and have a door and door opening assembly. The processor is in communication with the motors for rotating the housing and opening the doors. The processor has a storage medium for storing the cart's instrument dispensing history. The processor also has a user interface for capturing user input.

Abstract: The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopa-thy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres.

Abstract: A compound of Formula I: wherein: Y is —C(O)NHR1 or —NHC(O)R1; R1 is aryl; ?is ?optionally substituted with one or more substituents selected from the group consisting of oxo, F, Cl, Br, I, alkyl, NH2, NHR4, NHC(O)R4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; or ?is ?optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, NO2, alkyl, C(O)R4, C(O)NHR4, C(O)NR5R6, C(O)OH, C(O)OR4, NH2, NHR4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; each R4 is independently alkyl, cycloalkyl, or aryl; each R5 is independently alkyl, cycloalkyl, or aryl; each R6 is independently alkyl, cycloalkyl, or aryl; or each R5 and R6, together with the nitrogen atom to which they are attached, independently form an unsubstituted heterocyclic alkyl or unsubstituted heterocyclic aryl; and X is —S— or —O—; and n is 2, 3, or 4.

Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I)

Abstract: A system and method for relief of negative lung pressure during acute laryngospasm or upper airway obstruction, providing a non-toxic gas cartridge capable of supplying between 0.5-5 liters of gas during a procedure, a valve adapted to commence and stop gas release, and a trans-cricothyroid cartilage inflation needle for acutely relieving the negative pressure in the chest. The needle may also be used to insert a guidewire to assist in endotracheal tube insertion.

Abstract: The invention generally relates to a purified inactivated Zika virus (ZIKV), methods for producing the purified inactivated ZIKV, immunogenic compositions and vaccines comprising the purified inactivated ZIKV and methods for the prevention and/or treatment of infection by ZIKV.

Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:

Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (IAPP) polypeptides, which are more soluble at neutral pH than the wild-type human islet amyloid polypeptide (hIAPP) protein are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides to be delivered to a subject in a single injection with an insulin agent. Methods and pharmacological compositions for treating an abnormal condition, such as an amyloid-based disease or type-1 diabetes in a subject are also disclosed.

Abstract: There is set forth herein a method including a substrate; a dielectric stack disposed on the substrate; one or more photonics device integrated in the dielectric stack; and a laser light source having a laser stack including a plurality of structures arranged in a stack, wherein structures of the plurality of structures are integrated in the dielectric stack, wherein the laser stack includes an active region configured to emit light in response to the application of electrical energy to the laser stack.

Abstract: Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spa

Abstract: Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spa

Abstract: A method for detecting a risk of, diagnosing, prognosing, or monitoring anorexia nervosa or another eating disorder or for distinguishing a healthy subject from one with anorexia, an eating disorder, or an anxiety disorder comprising detecting at least one abnormal or altered pattern of miRNA and/or microbial RNA in biological sample compared to a control value from one or more normal subjects or healthy controls, and selecting a subject having at least one abnormal or altered pattern of miRNA and/or microbial RNA correlated with anorexia nervosa or another eating disorder. Probe and/or primer compositions for identifying miRNAs or microbial RNAs; compositions containing miRNAs or microbial RNAs, their mimics or agents that target miRNAs or microbial RNAs; and methods of treatment for AN and other eating disorders.

Abstract: A plasmonic phase modulator is provided. The modulator has a conductive layer, and a dielectric layer disposed on the conductive layer. A plasmonic layer is disposed on the dielectric layer. A plasmonic layer is disposed on the dielectric layer. The plasmonic layer is conductive to surface plasmon polariton (SPP) waves. The plasmonic layer may be, for example, a graphene sheet. A voltage signal source is operatively connected between the conductive layer and the plasmonic layer for modulating a propagation speed of an SPP wave propagating on the plasmonic layer.